Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

3(60.0%)

Phase 4

2(40.0%)

5Total

N/A(3)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT00528918Not ApplicableCompleted

Comparison of Apidra to Regular Insulin in Hospitalized Patients

Role: lead

NCT01181986Phase 4Completed

The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes

Role: lead

NCT00824694Not ApplicableCompleted

Impact of Accu-Chek 360 in Veterans With Type 2 Diabetes

Role: collaborator

NCT01154023Not ApplicableCompleted

Behavioral Intervention for Insomnia in Older Adults

Role: lead

NCT00974272Phase 4Completed

Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

Role: lead

NCT00767923Unknown

Validation of OxyVu for Assessing Level of Amputation With Comparison to Other Modalities

Role: collaborator

All 6 trials loaded